13/01/2026
Advancing the fight against “Super Gonorrhea” 🦠
We are thrilled to announce a landmark collaboration and license agreement with the Global Antibiotic R&D Partnership (GARDP) to develop Debio1453, a first-in-class antibiotic targeting 𝘕𝘦𝘪𝘴𝘴𝘦𝘳𝘪𝘢 𝘨𝘰𝘯𝘰𝘳𝘳𝘩𝘰𝘦𝘢𝘦, a bacteria that has developed resistance against nearly every antibiotic ever used to treat it.
💡 With 82M new cases of gonorrhea each year and rising drug resistance, this partnership is building on top of recent advances of new treatments developed to keep gonorrhea treatable for future generations.
Read the PR to learn more
https://www.debiopharm.com/drug-development/press-releases/gardp-and-debiopharm-partner-to-advance-development-of-novel-gonorrhea-drug/
